Combination drug regimens for metastatic clear cell renal cell carcinoma

Renal cell carcinomas (RCC) make up about 90% of kidney cancers, of which 80% are of the clear cell subtype. About 20% of patients are already metastatic at the time of diagnosis. Initial treatment is often cytoreductive nephrectomy, but systemic therapy is required for advanced RCC. Single agent ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Khetani, Viraj V, Portal, Daniella E, Shah, Mansi R, Mayer, Tina, Singer, Eric A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443831/
https://www.ncbi.nlm.nih.gov/pubmed/32879843
http://dx.doi.org/10.5306/wjco.v11.i8.541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443831/
https://www.ncbi.nlm.nih.gov/pubmed/32879843
http://dx.doi.org/10.5306/wjco.v11.i8.541

Ejemplares similares